Multiomics Tumour Profiling Guides Personalized Melanoma Treatment in Prospective TuPro Study
The Tumor Profiler precision oncology project applied nine independent single-cell and omics technologies to 126 melanoma samples, generating up to 500 GB of data per sample within four weeks. In 75% of cases, the molecular tumour board judged the multi-omic data useful for treatment recommendations. Among 37 difficult-to-treat patients receiving polybiomarker-driven beyond-standard-of-care therapy, the objective response rate was 38% with a disease control rate of 54%, demonstrating feasibility and clinical relevance of comprehensive omics-based tumour profiling.
The original study
Feasibility of multiomics tumor profiling for guiding treatment of melanoma.
- Authors
- Miglino N, Toussaint NC, Ring A, Bonilla X, Tusup M, Gosztonyi B, et al.
- Journal
- Nature medicine
- Type
- Journal Article, Multicenter Study, Observational Study
- PMID
- 40425842
Original abstract
There is limited evidence supporting the feasibility of using omics and functional technologies to inform treatment decisions. Here we present results from a cohort of 116 melanoma patients in the prospective, multicentric observational Tumor Profiler (TuPro) precision oncology project. Nine independent technologies, mostly at single-cell level, were used to analyze 126 patient samples, generating up to 500 Gb of data per sample (40,000 potential markers) within 4 weeks. Among established and experimental markers, the molecular tumor board selected 54 to inform its treatment recommendations. In 75% of cases, TuPro-based data were judged to be useful in informing recommendations. Patients received either standard of care (SOC) treatments or highly individualized, polybiomarker-driven treatments (beyond SOC). The objective response rate in difficult-to-treat palliative, beyond SOC patients (n = 37) was 38%, with a disease control rate of 54%. Progression-free survival of patients with TuPro-informed therapy decisions was 6.04 months, (95% confidence interval, 3.75-12.06) and 5.35 months (95% confidence interval, 2.89-12.06) in ≥third therapy lines. The proof-of-concept TuPro project demonstrated the feasibility and relevance of omics-based tumor profiling to support data-guided clinical decision-making. ClinicalTrials.gov identifier: NCT06463509 .